Adaptive Biotechnologies
Provides clonoSEQ residual-disease testing and immune-receptor discovery services.
$25.80
After-hours close+0.59 (+2.34%)
At close$25.21(−4.65%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 99.83%Insiders 3.01%
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 160.04M · Float 155.20M · 97.0% free float
Institutions13F, as of Jun 30, 2026
308 holders · 159.77M shares · 54 new positions · 164 increased · 86 reduced · 48 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Viking Global Investors LP | 29.99M | 18.74% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 15.14M | 9.46% | +1.84M | Aug 7, 2026 |
| Vanguard Capital Management LLC | 6.40M | 4.00% | +309.4K | Aug 13, 2026 |
| Wellington Management Group LLP | 5.91M | 3.69% | +2.05M | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 5.48M | 3.42% | +984.8K | Aug 13, 2026 |
| D. E. Shaw & Co., Inc. | 4.63M | 2.89% | +2.66M | Aug 14, 2026 |
| Westfield Capital Management Co LP | 4.27M | 2.67% | −1.17M | Aug 12, 2026 |
| Geode Capital Management, LLC | 3.64M | 2.28% | +5.8K | Aug 12, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Viking Global Investors LP | 18.80% | 29.99M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 7.90% | 11.99M | 13G | Jan 21, 2026 ↗ |
| Nikko Asset Management Co., Ltd. (“NAM”)incl. Sumitomo Mitsui Trust Group, Inc. (“SMTG”) | 5.24% | 7.73M | 13G | Nov 5, 2024 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Chad M. Robins | director, officer: CEO and Chairman | 2.18M | 1.36% | Aug 19, 2026 |
| Harlan S. Robins | officer: Chief Scientific Officer | 812.1K | 0.51% | Jul 23, 2026 |
| Susan Bobulsky | officer: Chief Commercial Officer, MRD | 397.0K | 0.25% | Aug 12, 2026 |
| Julie Rubinstein | officer: President and COO | 377.8K | 0.24% | Apr 29, 2026 |
| Kyle Piskel | officer: Chief Financial Officer | 256.7K | 0.16% | May 20, 2026 |
| Francis Lo | officer: Chief People Officer | 230.7K | 0.14% | Jul 17, 2026 |
| Sharon Benzeno | officer: Chief Commercial Ofc Imm Med | 221.3K | 0.14% | Jun 30, 2026 |
| Peter M. Neupert | director | 130.6K | 0.08% | Aug 19, 2026 |
| Katey Einterz Owen | director | 78.6K | 0.05% | Aug 28, 2026 |
| Michael J. Pellini | director | 69.7K | 0.04% | Mar 6, 2025 |
7 ten-percent owners hold 109.61M shares by Form 4, outside the officers-and-directors figure above · 33 people have not refiled in the last 18 months (17.99M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 26, 2026 | Katey Einterz Owendirector | Sale | 9,615 | $26.00 | 78,639 |
| Aug 18, 2026 | Robert Hershbergdirector | Sale · 2 lots | 30,664 | $24.40 | 46,683 |
| Aug 18, 2026 | Chad M. Robinsdirector, officer: CEO and Chairman | Sale · 2 lots | 278,676 | $24.48 | 2,180,518 |
| Aug 17, 2026 | Chad M. Robinsdirector, officer: CEO and Chairman | Sale · 2 lots | 321,324 | $25.08 | 2,180,518 |
| Aug 17, 2026 | Peter M. Neupertdirector | Sale · 3 lots | 124,690 | $25.15 | 130,625 |
| Aug 10, 2026 | Susan Bobulskyofficer: Chief Commercial Officer, MRD | Sale | 3,000 | $25.00 | 396,989 |
| Jul 30, 2026 | Susan Bobulskyofficer: Chief Commercial Officer, MRD | Sale | 1,299 | $24.00 | 399,989 |
| Jul 21, 2026 | Harlan S. Robinsofficer: Chief Scientific Officer | Sale · 2 lots | 492,400 | $21.89 | 812,058 |
| Jul 16, 2026 | Susan Bobulskyofficer: Chief Commercial Officer, MRD | Sale | 5,000 | $23.00 | 401,288 |
| Jul 15, 2026 | Francis Loofficer: Chief People Officer | Sale | 105,762 | $22.59 | 230,713 |
CongressHouse and Senate disclosures
Not reported.